Sirnaomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapeutics for significant human diseases using RNA interference (RNAi) technology. Founded in 2007 and headquartered in Gaithersburg, Maryland, with additional offices in Cambridge, Massachusetts, and facilities in Suzhou and Guangzhou, China, Sirnaomics is dedicated to addressing critical medical needs in oncology, anti-fibrotic therapeutics, and viral infections. The company's product portfolio includes several small interfering RNA (siRNA) therapeutics such as STP705 for scar reduction, STP909 for colon cancer, and STP900 for HPV and cervical cancer, among others. Sirnaomics employs proprietary Polypeptide Nano-Particle (PNP) technology to enhance drug delivery, allowing effective targeting of the tumor microenvironment and various cell types, particularly in the liver. Through its innovative approach, Sirnaomics aims to create impactful treatments for diseases with large market opportunities.
Baisios is a developer of tumor immune cell therapy technology and is dedicated to the growth of the tumor biotherapy industry.
EDIRNA
Corporate Round in 2023
EDIRNA is an innovative biotech company focused on RNA-Editing technology discovers and develops edit-to cure therapeutics for undruggable target conditions.
RNAimmune
Series A in 2022
RNAimmune, Inc. is a biopharmaceutical company focused on the development of messenger RNA (mRNA) therapeutics and vaccines. Based in Gaithersburg, Maryland, the company utilizes mRNA as a data carrier to instruct the human body to produce proteins that combat a variety of diseases, including cancer, viral infections, and rare diseases. RNAimmune has developed an mRNA design platform and self-amplifying mRNA technology, alongside a proprietary artificial intelligence algorithm known as ALEPVA, which aids in antigen prediction and vaccine design. The company is a spin-off from Sirnaomics, Inc. and holds exclusive rights to the Polypeptide Lipid Nanoparticle (PLNP) technology for mRNA delivery. By integrating these innovative technologies, RNAimmune aims to create a robust platform for mRNA drug discovery and development, addressing significant unmet medical needs in the industry.
RNAimmune
Seed Round in 2021
RNAimmune, Inc. is a biopharmaceutical company focused on the development of messenger RNA (mRNA) therapeutics and vaccines. Based in Gaithersburg, Maryland, the company utilizes mRNA as a data carrier to instruct the human body to produce proteins that combat a variety of diseases, including cancer, viral infections, and rare diseases. RNAimmune has developed an mRNA design platform and self-amplifying mRNA technology, alongside a proprietary artificial intelligence algorithm known as ALEPVA, which aids in antigen prediction and vaccine design. The company is a spin-off from Sirnaomics, Inc. and holds exclusive rights to the Polypeptide Lipid Nanoparticle (PLNP) technology for mRNA delivery. By integrating these innovative technologies, RNAimmune aims to create a robust platform for mRNA drug discovery and development, addressing significant unmet medical needs in the industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.